KeyCorp Increases ICU Medical (NASDAQ:ICUI) Price Target to $209.00

ICU Medical (NASDAQ:ICUI) had its target price upped by equities research analysts at KeyCorp from $198.00 to $209.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock. KeyCorp’s target price would indicate a potential upside of 21.54% from the stock’s current price.

Several other research firms have also recently weighed in on ICUI. StockNews.com cut ICU Medical from a “buy” rating to a “hold” rating in a report on Tuesday. Jefferies Financial Group initiated coverage on shares of ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Wednesday. Finally, Raymond James lifted their target price on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, ICU Medical has an average rating of “Moderate Buy” and a consensus price target of $173.00.

ICU Medical Trading Down 1.6 %

Shares of ICUI opened at $171.96 on Wednesday. ICU Medical has a 1 year low of $82.82 and a 1 year high of $196.26. The company has a quick ratio of 1.08, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The stock has a 50 day simple moving average of $176.32 and a two-hundred day simple moving average of $142.19.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.35. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. The company had revenue of $580.07 million during the quarter, compared to analyst estimates of $574.77 million. On average, equities analysts anticipate that ICU Medical will post 3.81 EPS for the current fiscal year.

Insider Transactions at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at $17,973,261.12. This trade represents a 10.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now directly owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. This represents a 16.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,502 shares of company stock valued at $6,573,496 in the last three months. 6.70% of the stock is currently owned by company insiders.

Institutional Trading of ICU Medical

Institutional investors have recently added to or reduced their stakes in the business. Silvercrest Asset Management Group LLC boosted its position in shares of ICU Medical by 109.4% during the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock valued at $29,882,000 after buying an additional 145,485 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of ICU Medical by 2,966.3% during the 2nd quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier’s stock valued at $16,844,000 after acquiring an additional 137,222 shares during the last quarter. Millennium Management LLC grew its stake in shares of ICU Medical by 327.8% in the second quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier’s stock worth $16,158,000 after acquiring an additional 104,264 shares during the period. FMR LLC raised its holdings in shares of ICU Medical by 2,676.6% during the third quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier’s stock valued at $18,968,000 after purchasing an additional 100,345 shares during the last quarter. Finally, Granite Investment Partners LLC bought a new position in ICU Medical during the second quarter valued at approximately $10,650,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.